期刊文献+

抗帕金森病药物药理研究进展 被引量:5

下载PDF
导出
摘要 据报道,美国现有帕金森病(PD)患者约150万,每年用于治疗PD的费用高达100亿美元。研究报告显示,我国65岁以上PD患病率男性为1.7%,女性为1.6%,位居老年神经系统退行性疾病第2位。PD是一种终身性疾病,一旦患病则需终身治疗,药物治疗仍是目前最主要的方法。常用的临床治疗药物包括多巴胺类和抗胆碱能药物。本文就抗PD药物约理研究进展综述如下。1PD发病机制PD是中、老年人常见的一种中枢神经系统锥体外系功能障碍的慢性进行性疾病。
出处 《临床合理用药杂志》 2011年第9期130-131,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献8

  • 1Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China:prevalence in Beijing, Xi'an and Shanghai [ J ]. Lancet, 2005,365 ( 9459 ) : 595 - 597.
  • 2尹琳琳,朱兴族.帕金森病的发病机制及其药物治疗研究进展[J].国外医学(药学分册),2006,33(2):93-96. 被引量:13
  • 3Ebadi M,Sharma S, Shavali S, et al. Neuroprotective actions of selegiline [ J ]. J Neurosci Res,2002,67 ( 3 ) : 285 - 289.
  • 4孙斌.抗帕金森病新药——托卡朋与恩他卡朋[J].医药导报,2003,22(2):71-74. 被引量:7
  • 5Hadj TA, Gregoire L, Bangassoro E, et al. Sustained cabergoline treatment reveres levodopa-induced dyskinesias in parkinsonian monkeys [ J ]. Clin Neuropharmaco1,2000,23 (4) : 195 - 202.
  • 6Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson' s disease [ J ]. Parkinsonism Retat Disord,2001,7(2) :115 - 120.
  • 7Calne D,Schulzer M, Mak E,et al. Treatment for the progression of Parkinson's disease [ J ]. Lancet Neurol, 2005,4 (4) :206.
  • 8Moresco RM, Volonte MA, Messa C, et al. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET-[ ( 11 )C ] raclopride study [ J ]. J Neural Transm, 2002,109 ( 10 ) : 1265 - 1274.

二级参考文献20

  • 1Hohhoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits[J]. Ann Neurol, 1994, 36(2) :176- 182.
  • 2Yoshino H, Hattori Y, Imai H, et al. Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease[J]. Rinsho Shinkeigaku, 1993, 33(3):261- 265.
  • 3Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases[J]. Proc Natl Acad Sci USA, 1990, 87(11):4078-4082.
  • 4Zhang P, Land W, Lee S, et al. Electron tomography of degenerating neurons in mice with abnormal regulation of iron metabolism[J].J Struct Biol, 2005, 150(2) : 144 - 153.
  • 5Defazio G, Dal Toso R, Benvegnu D, et al. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture[J]. Brain Res, 1994, 633(1/2) :206 - 212.
  • 6McGeer PL, Itagaki S, Boyes BE. Reactive microglia are positive for HLA-DR in the substantia nigra of Parldnson's and Alzheimer's disease brains[J]. Neurology, 1988, 38(8):1285- 1291.
  • 7Le WD, Colom LV, Xie WJ, et al. Cell death induced by beta-amyloid 1-40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis[J]. Brain Res,1995, 686(1):49- 60.
  • 8Tamas A, Lubics A, Szalontay L, et al. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats [ J ]. Behav Braon Res,2005, 158(2) :221 - 229.
  • 9Swope DM. Rapid treatment of "wearing off" in Parkinson's disease[J]. Neurology, 2004, 62(6 Suppl 4):S27- S31.
  • 10Kihara T, Shimohama S, Sawada H, et al. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade[J]. J Neurosci Res, 2002, 70(3):274-282.

共引文献18

同被引文献52

引证文献5

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部